ESI-GROUP/FAW-VW
2.4.2024 08:01:33 CEST | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI) and FAW-Volkswagen (FAW-VW) TE have commemorated their strategic partnership with the signing of a Memorandum of Understanding (MoU) aimed at advancing intelligent simulation technology within the automotive industry. The ceremony, held at the FAW-VW R&D center in Changchun, Jilin Province, PRC, was officiated by Deng Guohui, Technical Development Director at FAW-VW, and Francis Griffiths, Executive Vice-President and Chief Revenue Officer at ESI Group.
The collaboration between ESI Group and FAW-VW TE aims to address the challenges posed by China's automotive safety regulations and drive industry innovation. Through this partnership, the two entities will aim to drive innovation and efficiency in intelligent simulation, and work towards establishing a localized automotive industry material database, thereby enhancing cooperation in advancing intelligent simulation technology across the industry. This collaborative effort is geared toward paving the way for a cleaner, safer, and more productive future.
Under the MoU, a material testing and intelligent simulation joint laboratory has been established, marking a significant step forward in intelligent simulation, innovation, and research within the automotive sector.
“With over 40 years of collaboration, ESI Group and VW Group have built strong ties, including a fruitful partnership with FAW-VW since 2007. This marks a significant milestone in our commitment to advancing virtual simulation technology in the automotive sector. Together with FAW-Volkswagen, we aim to drive innovation and efficiency in intelligent simulation, materials research and development,” declared Francis Griffiths, Executive Vice-President, Chief Revenue Officer at ESI Group.
"Today's milestone event celebrates not only two decades of fruitful collaboration but also embarks on a new era of innovation in automotive virtual simulation with ESI. This partnership signifies more than a formal agreement; it is a testament to our shared vision and commitment, aiming to pioneer intelligent simulation and materials research, setting new industry standards, and driving automotive safety and efficiency forward." declared Deng Guohui, Technical Development Director at FAW-VW.
During the ceremony, FAW-VW TE and ESI Group exchanged awards to honor their collaborative achievements in innovation. FAW-VW TE awarded ESI Group the prestigious "CAE Trusted Advisor" award, recognizing ESI's outstanding support in advancing virtual simulation technology in the automotive industry.
ESI Group reciprocated by presenting multiple global awards to FAW-VW's Technology Development team, including "Best Cooperation Partner" represented by Deng Guohui, Technical Development Director at FAW-VW and "Best Simulation Method Development Team" represented by Fu Xiaolong. Li Dapeng was also honored with the "'Virtual Performance Expert" award for their exceptional contributions. These accolades underscore the mutual respect, shared goals, and commitment of both companies to advancing automotive safety and efficiency through successful collaboration.
About ESI Group
ESI Group, a part of Keysight Technologies, provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise. Acting principally in automotive, land transportation, aerospace and defense, and heavy industry, ESI software enables engineers to simulate mechanical designs, smart manufacturing processes, and human-centric workflows to make better decisions earlier in the product lifecycle. Keysight is an S&P 500 company delivering market-leading design, emulation, and test solutions to help engineers develop and deploy faster, with less risk, throughout the entire product lifecycle. For further information, go to: www.esi-group.com
Follow ESI LinkedIn | Facebook | Twitter | YouTube
About FAW-Volkswagen
Established on February 6, 1991, FAW-Volkswagen Automotive Co., Ltd. (hereinafter referred to as FAW-Volkswagen) is a large-sized passenger auto manufacturer jointly managed by First Automotive Group Corporation, Volkswagen AG, Audi AG and Volkswagen (China) Investment Co., Ltd. It is the domestic first modern passenger auto manufacturer constructed according to the economic scale.
Through the development of around 30 years, FAW-Volkswagen has had the capacity layout in Changchun in the Northeast, Chengdu in the Southwest, Foshan in South China, Qingdao in East China and Tianjin in North China. It boasts eight professional manufacturing factories, namely No. 1 Car Factory, No. 2 Car Factory, No. 3 Car Factory, No. 4 Car Factory, No. 5 Car Factory, No. 6 Car Factory, Business Division of Power Assembly, and Punching Center.
Add: No. 5 Anqing Road, Auto Industry Development District, Changchun Jilin Province, PRC
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401600103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom